Journavx

## What is Journavx (Suzetrigine)?

Journavx (suzetrigine) is a landmark prescription medication that earned FDA approval in January 2025 — the first new class of non-opioid analgesic for moderate-to-severe acute pain in over 20 years. Developed by Vertex Pharmaceuticals, Journavx targets a protein called Nav1.8, a voltage-gated sodium channel found almost exclusively on peripheral pain-sensing nerve fibers. This represents a fundamentally different approach from opioids, which act on receptors in the brain and spinal cord.

Journavx is indicated for the treatment of moderate-to-severe acute pain in adults. It was studied and approved based on clinical trials in patients undergoing abdominoplasty (tummy tuck surgery) and bunionectomy (foot surgery), two models of acute postoperative pain that are widely accepted by the FDA as proxies for broader surgical pain.

The arrival of Journavx is significant in the context of the ongoing opioid epidemic in the United States. Millions of Americans are prescribed opioids for acute pain following surgery or injury each year, and for a subset of these patients, short-term opioid exposure contributes to long-term dependence, misuse, or overdose. A non-opioid medication that provides comparable pain relief without opioid-related risks addresses a major unmet clinical need.

---

## How Does Journavx Work?

Journavx works through a highly selective mechanism targeting the Nav1.8 sodium channel. To understand why this matters, it helps to understand how pain signals travel through the body.

When tissue is damaged — by surgery, injury, or inflammation — specialized nerve endings called nociceptors detect the threat. These nerve endings fire electrical signals (action potentials) that travel along sensory nerve fibers to the spinal cord and then to the brain, where pain is perceived. The firing of these action potentials depends on the rapid influx of sodium ions through voltage-gated sodium channels in the nerve cell membrane.

Nine different Nav (sodium channel) subtypes exist in the human body (Nav1.1 through Nav1.9), each expressed in different tissues. Nav1.8 is found predominantly on peripheral pain-sensing neurons — the C-fibers and A-delta fibers that transmit acute pain signals. It is notably absent from cardiac tissue, skeletal muscle, and most central nervous system neurons.

Suzetrigine binds to and blocks Nav1.8 when the channel is in an inactivated (non-conducting) state. This stabilization prevents the channel from cycling back into its active state, thereby blocking repetitive action potential firing in peripheral nociceptors. The result is that pain signals from the injury site are blocked before they ever reach the spinal cord and brain.

This peripheral selectivity is what sets Journavx apart. Because it does not engage opioid receptors, it produces no euphoria, no physical dependence, no risk of respiratory depression, and no addiction. Because it does not target Nav1.5 (the cardiac sodium channel) or Nav channels in the central nervous system, it lacks the arrhythmia risks of local anesthetics and the CNS toxicity of non-selective sodium channel blockers.

---

## Approved Uses and Indications

Journavx is FDA-approved for moderate-to-severe acute pain in adults. Its clinical development focused on surgical pain, and the pivotal trials (APOLLO-1 and APOLLO-2) demonstrated statistically significant and clinically meaningful reductions in pain scores compared to placebo in patients recovering from bunionectomy and abdominoplasty, respectively.

In clinical practice, physicians may use Journavx in the following situations:

• Post-surgical pain management — particularly in patients where opioid use is undesirable, such as those with a history of substance use disorder, respiratory compromise, opioid-induced nausea, or extreme opioid sensitivity.
• Multimodal analgesia — combined with acetaminophen, NSAIDs, or regional nerve blocks as part of a comprehensive pain management plan that minimizes total opioid exposure.
• Opioid-sparing strategies — in healthcare settings implementing Enhanced Recovery After Surgery (ERAS) protocols.
• Acute musculoskeletal pain in adults where opioids are typically prescribed but alternatives are clinically preferable.

It is important to note that Journavx is not approved for chronic pain, neuropathic pain, or pain in pediatric patients.

---

## Dosage and How to Take Journavx

### Adult Dosing

• Loading dose: 100 mg taken orally once, on an empty stomach, to rapidly reach therapeutic drug levels.
• Maintenance dose: 50 mg taken orally every 12 hours (twice daily), also on an empty stomach.
• Duration: Clinical trials evaluated up to 14 days of use.

### Critical Administration Requirement: Take on an Empty Stomach

This is one of the most important instructions for patients taking Journavx. Food — particularly high-fat meals — significantly increases how much suzetrigine is absorbed by the body, dramatically raising peak blood concentrations. This increases the risk of adverse effects including dizziness and hypersensitivity reactions.

Patients must take Journavx: - At least 1 hour before eating a meal, OR - At least 2 hours after finishing a meal.

Do not crush, chew, or split the tablet. Swallow it whole with water.

### Dosing in Special Populations

• Mild-to-moderate renal impairment: No dose adjustment required.
• Mild-to-moderate hepatic impairment (Child-Pugh A or B): No dose adjustment required.
• Severe hepatic impairment (Child-Pugh C): Not recommended due to markedly increased drug exposure.
• Elderly patients: No dose adjustment based on age, but monitor closely for dizziness and CNS effects.
• Pediatric patients: Not approved for use in patients under 18 years of age.

---

## Side Effects of Journavx

### Common Side Effects

Most patients tolerate Journavx well. The most frequently reported adverse effects in clinical trials include:

• Dizziness (approximately 10–12%)
• Drowsiness/somnolence (6–8%)
• Nausea (5–7%)
• Headache (5–7%)
• Constipation (4–6%)
• Itching/pruritus (4–5%)
• Rash (3–5%)
• Fatigue (3–4%)
• Vomiting (3–4%)
• Muscle spasms (2–4%)
• Numbness or tingling (paresthesia/hypoesthesia) (2–3%)
• Hot flushes (2–3%)

### Serious Side Effects

Although uncommon, the following serious adverse effects have been reported and require prompt medical attention:

• Severe hypersensitivity reactions including anaphylaxis and angioedema — characterized by throat swelling, difficulty breathing, severe rash, or rapid heart rate. Discontinue immediately and seek emergency care.
• DRESS (Drug Rash with Eosinophilia and Systemic Symptoms) — a potentially life-threatening hypersensitivity syndrome with fever, widespread rash, lymph node swelling, and organ involvement.
• Severe skin reactions — such as erythema multiforme.
• Toxicity from CYP3A4 drug interactions — significantly elevated suzetrigine blood levels caused by prohibited drug combinations can produce amplified versions of any side effect, including severe dizziness, altered consciousness, and dangerous allergic reactions.

---

## Drug Interactions with Journavx

Understanding Journavx drug interactions is essential for safe prescribing and patient counseling. Suzetrigine is primarily metabolized by the CYP3A4 enzyme in the liver, making it highly susceptible to drug interactions with medications that inhibit or induce this enzyme system.

### Contraindicated Combinations (Do Not Use Together)

Strong CYP3A4 Inhibitors — these drugs block CYP3A4, causing suzetrigine levels to rise dramatically (up to 13-fold in some studies): - Antifungals: ketoconazole, itraconazole, voriconazole, posaconazole - Antibiotics: clarithromycin, telithromycin - HIV medications: ritonavir, cobicistat, lopinavir/ritonavir, indinavir - Other: nefazodone

Strong CYP3A4 Inducers — these drugs accelerate CYP3A4 activity, reducing suzetrigine to potentially subtherapeutic levels (up to 83% reduction): - Antibiotics: rifampin (rifampicin) - Antiseizure medications: carbamazepine, phenytoin, phenobarbital, primidone - Herbal supplements: St. John's Wort (Hypericum perforatum)

### Interactions Requiring Caution or Avoidance

Moderate CYP3A4 Inhibitors (increase suzetrigine levels approximately 3-fold — avoid or use with extreme caution): - Fluconazole, erythromycin, diltiazem, verapamil, aprepitant, cimetidine - Grapefruit and grapefruit juice — patients must avoid grapefruit products during Journavx therapy.

Moderate CYP3A4 Inducers (reduce suzetrigine effectiveness): - Efavirenz, modafinil, bosentan, nafcillin

Additive CNS Depression (use caution when combining): - Opioid analgesics (morphine, oxycodone, hydrocodone, fentanyl) - Benzodiazepines (alprazolam, lorazepam, diazepam) - Gabapentinoids (gabapentin, pregabalin) - Muscle relaxants (cyclobenzaprine, methocarbamol) - Antihistamines with sedating properties - Alcohol

### Practical Guidance for Clinicians and Patients

Before prescribing or dispensing Journavx, a thorough medication reconciliation review should be performed. Patients should provide a complete list of all prescription drugs, over-the-counter medications, vitamins, and herbal products. Pharmacists play a critical role in identifying potential CYP3A4 interactions before the patient leaves the pharmacy.

---

## Warnings and Precautions

Do not take Journavx if you are taking strong CYP3A4 inhibitors or inducers. This is the most critical safety message. The drug interaction risk with these agents is severe enough that concurrent use is contraindicated in the prescribing information.

Hypersensitivity: Stop taking Journavx and seek emergency medical care immediately if you develop signs of a serious allergic reaction: difficulty breathing, swelling of the face, lips, tongue, or throat, severe skin rash, hives, rapid heartbeat, or dizziness that makes you feel like you might faint.

Hepatic impairment: Patients with severe liver disease should not use Journavx due to accumulation of the drug. Moderate liver disease does not require dose adjustment, but patients should be monitored.

Driving: Journavx can impair driving ability due to dizziness and drowsiness. Avoid driving or operating heavy machinery until you understand how this medication affects you.

Elderly patients: Older adults may be more sensitive to the CNS effects of Journavx. Caregivers and patients should be vigilant about fall risk from dizziness.

---

## Pregnancy and Breastfeeding

Pregnancy: Animal reproductive toxicity studies have not shown adverse effects on fetal development at clinically relevant exposures. However, there are no adequate and well-controlled studies in pregnant women. Journavx should be used during pregnancy only if the potential benefit clearly justifies the potential risk to the fetus.

Breastfeeding: It is not known whether suzetrigine is present in human breast milk or whether it could harm a nursing infant. The developmental and health benefits of breastfeeding should be weighed against the mother's clinical need for Journavx, as well as any potential adverse effects on the breastfed infant.

Females and Males of Reproductive Potential: Based on animal studies, no impairment of fertility is expected at human therapeutic exposures.

---

## Storage Instructions

• Store at room temperature: 68°F to 77°F (20°C to 25°C)
• Brief excursions between 59°F and 86°F (15°C to 30°C) are permitted
• Store in the original container, tightly closed
• Protect from moisture and light
• Keep out of reach of children and pets
• Do not use after the expiration date printed on the container
• Dispose of unused medication through a medicine take-back program; do not flush unless the label specifically instructs it

---

## Frequently Asked Questions

Is Journavx addictive? Based on its mechanism of action and clinical trial data, Journavx is not expected to cause physical dependence, tolerance, or addiction. It does not act on opioid receptors or any known reward pathway in the brain. The FDA has not classified it as a controlled substance.

How quickly does Journavx work? The 100 mg loading dose is designed to rapidly achieve therapeutic blood levels. Patients in clinical trials reported meaningful pain relief beginning within a few hours of the first dose, with sustained analgesia throughout the twice-daily dosing period.

Can Journavx be taken with acetaminophen (Tylenol) or ibuprofen? There are no known pharmacokinetic interactions between suzetrigine and acetaminophen or standard NSAIDs like ibuprofen. Journavx may be used as part of a multimodal pain regimen. However, consult your doctor or pharmacist before combining any medications.

What happens if I accidentally take Journavx with food? Taking Journavx with food increases drug absorption and may raise the risk of side effects. If you realize you took it with a meal, do not take an extra dose to compensate. Take your next dose as scheduled on an empty stomach, and contact your pharmacist or doctor if you are concerned about symptoms.

---

## Summary

Journavx (suzetrigine) is a scientifically innovative and clinically important addition to the pain management toolkit. As the first selective Nav1.8 sodium channel blocker approved for human use, it offers meaningful acute pain relief through a mechanism that is fundamentally distinct from opioids, traditional NSAIDs, and local anesthetics. Its approval reflects years of research into the peripheral biology of pain and opens a new chapter in non-opioid analgesic therapy.

Its most significant clinical considerations are the mandatory fasted administration requirement, and the strict contraindication with strong CYP3A4 inhibitors and inducers. With appropriate patient selection and careful medication review, Journavx provides clinicians and patients with a well-tolerated, effective, non-opioid option for acute pain management.